New evidence from a Chinese cohort presented at the European Lung Cancer Congress (ELCC) 2026 shows that one-time low-dose ...
"Lung cancer remains a devastating disease, and Prof. Yarden's approach to tackling drug resistance with bispecific antibodies is precisely the kind of bold, out-of-the-box science that can transform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results